General R&D scope
When the next big advance happens in critical care, we plan to be there
- A rich late-stage pipeline focusing on compounds that are promising in critical care
- iNO and H2S : each has broad potential in critical care
- Terlipressin, BL-1040 and Fibrex Portfolio: acquired assets that hold great promise
- Continuous investment in preclinical programs and exploratory studies in critical care conditions
- Proven execution of complex clinical studies in ICU settings
- 3,500 ICU patients studied around the world
- More than 550 patients enrolled in 23 ongoing studies
- Commitment to minimize risk in clinical development through
- Active licensing & acquisition efforts to build on our portfolio